Open Access Article
This Open Access Article is licensed under a Creative Commons Attribution 3.0 Unported Licence
Correction: Targeting Brd4 for cancer therapy: inhibitors and degraders
Yingchao
Duan
a,
Yuanyuan
Guan
a,
Wenping
Qin
a,
Xiaoyu
Zhai
a,
Bin
Yu
*b and
Hongmin
Liu
*b
aSchool of Pharmacy, Xinxiang Medical University, Xinxiang, Henan 453003, China
bKey Laboratory of Advanced Pharmaceutical Technology, Ministry of Education of China, Co-innovation Center of Henan Province for New Drug R & D and Preclinical Safety, Institute of Drug Discovery and Development, School of Pharmaceutical Sciences, Zhengzhou University, 100 Kexue Avenue, Zhengzhou, Henan 450001, China. E-mail: zzuyubin@hotmail.com; liuhm@zzu.edu.cn
First published on 14th January 2019
Abstract
Correction for ‘Targeting Brd4 for cancer therapy: inhibitors and degraders’ by Yingchao Duan et al., Med. Chem. Commun., 2018, 9, 1779–1802.
The authors regret that some chemical structures are not correct in their review article entitled ‘Targeting Brd4 for cancer therapy: inhibitors and degraders’. The corrected structures for compound 20 in Fig. 4, compounds 26–35 in Fig. 6, compounds 96–98 in Fig. 21 and compounds 102–104 in Fig. 23 are shown below.
The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.
| This journal is © The Royal Society of Chemistry 2019 |